Novartis Hits Par With Second Lotrel Suit
Swiss pharmaceutical giant Novartis International AG has filed another patent suit against Par Pharmaceuticals, seeking to protect the market for billion-dollar hypertension treatment Lotrel....To view the full article, register now.
Already a subscriber? Click here to view full article